In 2024 ALMEA received a patent on the almea DR-DHQ-1 complex. At its core is encapsulated dihydroquercetin: the active stays stable in the formula longer.
The complex was developed in the company’s laboratory in Saint Petersburg.
The patent was one of the grounds on which ООО «АЛМЕА» received Skolkovo project participant status in 2026.